The RELENT Project
The RELENT Project
The RELENT Project

RELENT - RELapses prevENTion in chronic autoimmune disease: common mechanisms and co-morbidities


Chronic autoimmune diseases, such as rheumatoid arthritis and vasculitis, affect approximately eight percent of the population in industrialised countries. In many cases, the disease has a mild progression, but can also lead to a chronic and serious illness. 

Which patients will develop a severe course of autoimmune diseases?


"There is currently no means to distinguish at the outset those patients who will suffer from frequent relapses, and therefore need intensive early treatment, from those who do not. Titrating the use of immunosupression to the disease activity and developing novel treatment strategies consequently requires the application of precision medicine to autoimmunity –  a concept already established in cancer treatment,” states Prof. Renate Kain, coordinator of the project.


In order to better understand the common mechanisms of these diseases, the RELENT project will analyse data from a variety of measurements (clinical, serological, genetic, transcriptome) and thus develop new bio-markers for these diseases. These should allow the tailoring of the most efficacious treatment to each patient with a chronic autoimmune disease. Nearly six million Euros has been awarded to the RELENT consortium for the next 4.5 years by the European Commission under its Horizon 2020 programme. 



This website contains further details undefinedabout the project as well as the undefinedconsortium members. You will also find a section undefinedfor patients and undefinednews about RELENT. Please undefinedcontact us with any questions regarding the project.

Tweets by RELENT


News Section

The understanding of AAV pathogenesis isincreasing, leading to improvements in... Read more

Social Media